Research and Markets (http://www.researchandmarkets.com/research/56a15b/lithuania_pharmace) has announced the addition of the "Lithuania Pharmaceuticals and Healthcare Report Q4 2009" report to their offering.
Lithuania Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Lithuania's pharmaceuticals and healthcare industry.
BMI calculates that Lithuania's pharmaceutical market reached a value of LTL1.70bn (US$0.70bn) in 2008. By 2013, we expect the value of the prescription and over-the-counter (OTC) markets to reach a value of LTL2.13bn, equating to a compound annual growth rate (CAGR) of 4.61% over the forecast period. However, as a result of the weakening Lithuanian currency, drug market expenditure in US dollar terms will decline in 2009, to reach a value of US$0.526bn, before rising to US$0.528bn in 2010 and US$0.61bn by 2013, equating to a negative CAGR of -2.75%. We also add that the growth in the drug market is modest, in line with other Central and Eastern Europe (CEE) countries.
In BMI's Business Environment Ratings matrix for Q409, Lithuania is found in 16th position out of the 20 markets surveyed in the CEE region, between Moldova and Latvia. In relation to the previous quarter, Lithuania has moved down one place. The country's overall pharmaceutical rating is below average, due to small and falling population numbers that limit its overall size and an economy that is highly exposed to external risk. Globally, Lithuania is 55th of the 71 markets within BMI's pharmaceuticals and healthcare market universe, ahead of Morocco and Latvia and behind Indonesia and Israel.